← k3vl4r
Log inGet started →

PRME (Prime Medicine Inc) Price Forecast

AI-generated price forecast for Prime Medicine Inc (PRME) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

As of July 2026: K3vl4r's AI model currently reads PRME as 2/2 bullish · strong across its horizons (2 of 2 timeframes pointing up), with a last price of 2.98. See our public, auditable track record →

📈 Daily Top Picks beating the S&P 500 since launch→✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP

Last price

2.98

AI outlook

2/2 bullish · STRONG

Timeframes up

2 / 2

Share𝕏 Post✈ Telegram

PRME forecast by horizon

HorizonDirectionProjected move (end of horizon)Bullish prob.
1-hour~10 days out———
4-hour~2 months out———
Daily~5 months out▲ Up+30.66%100%
Weekly~1.9 years out▲ Up+41.95%—

Latest PRME news

From the market-news feed the forecasts are read against.

  • Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027 · Benzinga · Jul 23
  • Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable · SeekingAlpha · Jul 9
  • Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To Beam · Benzinga · Jul 8
  • Here’s Why H.C. Wainwright Upgraded Prime Medicine (PRME) To “Buy” · Insider Monkey · Jul 5
  • Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? · Zacks · Jul 3

🔒

See the full PRME forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

PRME forecast — frequently asked

Will PRME go up?

K3vl4r's AI model currently reads PRME as 2/2 bullish · STRONG — 2 of 2 forecast horizons point up, so the overall read is leaning to the upside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the PRME price prediction for 2026?

K3vl4r's model projects PRME toward $2.93 over the next ~5 months, a +0.3% move from $2.92. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What price could PRME reach?

Over its longest horizon (~~1.9 years), the model's projected target for PRME is $2.96 (+0.4% vs $2.95). Confidence decreases the further out the horizon, so treat longer-range targets as one scenario, not a guarantee. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

NAMSCNSPSHCTCRXCINGVORNTRARYTMCNTXHYPDSTTKSTIMAORTCAPR

Will PRME reach…?

Will PRME reach $5.00?Will PRME reach $10.00?Will PRME reach $20.00?

Or see the full PRME price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare PRME

PRME vs NAMSPRME vs CNSPPRME vs SHCPRME vs TCRXPRME vs CINGPRME vs VOR

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

k3vl4rTop PicksTrack recordChart indicatorsToday's outlookBiggest moversMarket heatmapForecasts by sectorAI reportsCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsPricingX (Twitter)Twitch — live forecastingDiscord community

Join the community on Discord and catch live forecasting on Twitch. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.